Andrea Bedan is a biopharma and device corporate account manager with over 20 years of experience in oncology sales and contracting. She has a track record of exceeding sales goals at multiple companies, including ranking #1 nationally at Spectrum Pharmaceuticals and GE Healthcare. Her expertise includes GPO and managed care contracting, reimbursement, and developing KOL relationships to drive sales.

1. ANDREA S. BEDAN
Targeting positions in Southeast / No relo needed (480) 338-7520 andreabedan@gmail.com
BIOPHARMA & DEVICE CORPORATE ACCOUNT MANAGER
Oncology GPOs | Specialty Wholesalers | Hospital & Provider Reimbursement | Contracting | Buy & Bill Insights
 Oncology practice GPO rebate contracting pull through, negotiation of large hospital GPO supply chain contracts, and
negotiation of volume-tiered managed care executive contracts.
 Reimbursement and clinical expertise in Medicare Part B buy-and-bill infused chemotherapeutics, Medicare Part A
instilled fluorescent agents and implanted radiological medical devices, Medicare Part B, Buy & Bill infused MAb
immunomodulators and radioimmunotherapies, and Medicare Part D self-injectable immunomodulators.
 Strategic partnerships within McKesson (OnMark, Unity,) Cardinal Health (VitalSource,) and AmerisourceBergen (ION)
GPO contracting teams.
 Regional and national oncology KOL development.
 Regional and DOD account management.
 OR and surgery center HIPAA certified and case qualified.
PROFESSIONAL EXPERIENCE
SPECTRUM PHARMACEUTICALS INC. 2014 – Present
Corporate Account Manager, Oncology Biotechnology – AZ / UT / NV
Present and pull through GPO pricing and rebate structured contracts to oncology C-suite, practice administrators and
pharmacy directors for infused chemotherapy Fusilev and radioimmunotherapy Zevalin. Drive contract adherence and
product sales in partnership with McKesson, AmerisourceBergen and Cardinal Health in liquid and solid tumor space.
Manage 1 clinical support specialist for account training purposes. Provide community practice and hospital reimbursement
direction and patient access support.
 Achieved 99% to goal Q3 2014; ranked #12 in nation; Achieved 101% to goal Q4 2014; ranked #14 in nation
 Achieved 127% to goal Q1 2015; ranked #1 in nation; Achieved 132% to goal Q2 2015; ranked #1 in nation
SIRTEX MEDICAL INC. 2013 - 2014
Oncology Market Development Manager, Oncology Medical Device
Develop Medical Oncology market and drive sales through medical oncology referrals to interventional radiologists for
infused SIR-Sheres radiological solid tumor medical device in the hospital OR setting. Develop national medical oncologist
KOL’s. Provide reimbursement support and insurance pre-determination access.
 Achieved 100% to goal Q4 2013
 Achieved 105% to goal Q1 2014; Achieved 114% to goal Q2 2014
GE HEALTHCARE 2009 - 2013
Western Regional Account Manager, Oncology Medical Device – Western US (26 states)
Manage and grow LDR Prostate and Lung Brachytherapy business. Launch hospital OR instilled fluorescent Cysview for
bladder cancer agent in top 100 academic, KOL and DOD accounts. Partner with Premier, Novation and MedAssets to win
hospital system, surgery center and GPO contracts via Materials Management and Finance departments. Manage billing,
coding and reimbursement support for all products. Provide clinical and technical expertise to US and internationally-based
urologists, radiation oncologists, medical physicists, thoracic surgeons and interventional radiologists in OR/surgery centers.
 Won Kaiser, Banner, Abrazo Health, Memorial and Sutter system LDR brachytherapy contracts. Increased regional
business 22% to $1.2M in a nationally declining market in 2010 and 2011.
 Ranked #2 in nation for LDR prostate brachytherapy; #1 ThinSeed launch; #2 LDR lung brachytherapy in 2011.
 Won formulary acceptance for Cysview at USC and VA Palo Alto; developed 2 international KOL’s.
BIOGEN IDEC, INC. 2004 – 2007
Area Business Manager, Neurology Biotechnology – Los Angeles & Central CA Relocation due to husband’s position
Launch infused MAb immunomodulator Tysabri and manage sales of injectable interferon Avonex for Multiple Sclerosis.
Rotate as Southern California Reimbursement Lead, Managed Care Advisor, and Marketing Advisor.
 Developed 2 physician KOL’s to drive formulary positioning at Cigna, Aetna, BCBS, PacifiCare, and UnitedHealthcare.
Won formulary acceptance for Tysabri at 5 key hospital accounts 3 months following launch.
 Drove sales through PBM’s and Specialty Pharmacy supply chains. Managed prior-authorization (PA) and appeals
processes for key accounts.
 Created clinical sales strategy that prevented Tysabri from cannibalizing Avonex sales. Grew Avonex sales 20%.
 Won 8 quarterly national sales contest awards for both Avonex and Tysabri based on sales maintained, sales
increased, and new patient starts.
 Ranked # 1 / 8 for Tysabri launch, 2005. Ranked #1 / 8 in region for Avonex sales, 2005, 2006, and 2007. Won
Leadership Circle in 2007.

2. CEPHALON INC. 2001 - 2004
Oncology Pain Care Specialist, Oncology Biotechnology
Launch oral transmucosal Actiq for breakthrough cancer pain to medical oncologists. Sell oral Provigil for narcolepsy and
wakefulness disorders to neurologists and psychiatrists. Develop regional KOL’s. Serve as Southern California Clinical Field
Trainer and Territory Analysis Trainer.
 Surpassed 2001 launch goal by 250%. Won President’s Club, Rookie of the Year, Representative of the Year, 2001.
 Surpassed 2002 sales goal by 318% and split territory in Q2. Won President’s Club in 2002.
 Surpassed 2003 sales goal by 85%. Ranked #2 of 85 for overall sales. Won National Sales Growth Contest, 2003.
 Surpassed 2004 sales goal by 84% following territory realignment. Ranked #10 of 145 for overall sales.
 #1 Producer in Southwest Sales Division in 2001, 2002, and 2003.
 Developed 3 Southern California KOL’s.
CYTOGEN CORPORATION 2001 –2001
Clinical Oncology Specialist, Oncology Medical Device and Imaging
Launch I-125 medical device BrachySeed for prostate cancer. Launch infused MAb ProstaScint for detection of prostate
cancer and infused MAb Oncoscint for detection of ovarian cancer. Provide reimbursement guidance to hospital imaging,
nuclear, pharmacy and purchasing departments including Kaiser, UCLA, USC, UCSD and Scripps networks.
 Ranked #1 of 6 in nation for BrachySeed procedures in 2001.
 Ranked #2 of 6 in nation for ProstaScint scans in 2001.
 Built Southern California Physician Champion Network.
ROCHE LABORATORIES 1998 - 2000
Hospital Sales Specialist, Critical Care Pharmaceutical
Drive formulary acceptance and hospital sales of injectable and infused Rocephin for community-acquired pneumonia, and
oral and infused Versed for anxiolysis, amnesia and anesthesia. Launch oral Xenical for obesity, oral Tamiflu for Influenza.
 Maintained and protected Rocephin formulary status against generic competition via physician champion relationships
and pharmacy contracting. Surpassed Rocephin sales goal by 120% in 1998.
 Established formulary protocols for ICU sedation at St. John’s Hospital and UCLA Medical Center. Increased Versed
sales 36% in 1999.
 Earned Achievement Award for territory business plan in 1998 and 1999.
EDUCATION
B.S., UNIVERSITY OF COLORADO, BOULDER, CO 1992 – 1996
Major: Psychology, Minor: Environmental, Population, Organismic Biology
Concentration: Neuroscience
Languages: English, Spanish
COMMUNITY SERVICE AND LEADERSHIP
ROSIE’S HOUSE, A MUSIC ACADEMY FOR CHILDREN, PHOENIX, AZ 2013 – Present
Board Member and Co-Chair of “Give Music…Give a Dream” Fundraising Campaign